U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07232719) titled 'A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight' on Nov. 14.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.
Participation in the study will last about 65 weeks and may include about 18 visits.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Intervention:
DRUG: Retatrutide
Administered SC
DRUG: Placebo
Administered SC
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Published by HT Digital Content Services with permission from Health Dail...